Boundless Bio Upgraded to Zacks Rank #2 After 34.5% EPS Estimate Surge
Boundless Bio received a Zacks Rank #2 (Buy) upgrade after its three-month consensus EPS estimate jumped 34.5%, placing it in the top 20% of ranked stocks. Analysts forecast a -$2.45 per share loss for fiscal 2025, unchanged year-over-year, reflecting improving earnings trends.
1. Upgrade Overview
Boundless Bio received a Zacks Rank #2 (Buy) upgrade, placing it in the top 20% of ranked stocks based on earnings estimate revisions.
2. Earnings Estimate Revisions
The Zacks Consensus Estimate for fiscal 2025 EPS rose 34.5% over the past three months to -$2.45 per share, indicating analysts’ increasingly optimistic view on the company’s earnings potential.
3. Implications for Stock Performance
Rising earnings estimates are a key driver of near-term stock movements, suggesting institutional investors may increase positions and potentially boost the share price.